{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:56:52Z","timestamp":1787241412639,"version":"build-2736575974"},"reference-count":17,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bio-Thera Solutions Ltd"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/14712598.2026.2663826","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:14:55Z","timestamp":1776921295000},"page":"515-524","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study"],"prefix":"10.1080","volume":"26","author":[{"given":"Honghu","family":"Tang","sequence":"first","affiliation":[{"name":"West China Hospital of Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dokoupilova","sequence":"additional","affiliation":[{"name":"Medical Plus, s.r.o","place":["Uhersk\u00e9 Hradi\u0161t\u011b, Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Batko","sequence":"additional","affiliation":[{"name":"Malopolskie Badania Kliniczne Sp. z o.o","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Zawadzki","sequence":"additional","affiliation":[{"name":"Reum-Medica S.C. Bozena Kowalewska, Marek Zawadzki","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastas","family":"Batalov","sequence":"additional","affiliation":[{"name":"University Hospital \u201cKaspela\u201d, Medical University of Plovdiv","place":["Plovdiv, Bulgaria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6283-8229","authenticated-orcid":false,"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"West China Hospital of Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Yang","sequence":"additional","affiliation":[{"name":"Bio-Thera Solutions Ltd","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinbo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Bio-Thera Solutions Ltd","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Dong","sequence":"additional","affiliation":[{"name":"Bio-Thera Solutions Ltd","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9234-5457","authenticated-orcid":false,"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"West China Hospital of Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"e_1_3_7_3_1","unstructured":"European Medicines Agency. Simponi (golimumab). European public assessment report (EPAR). 2026 [cited 2026 Mar 7]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/simponi-epar-product-information_en.pdf"},{"key":"e_1_3_7_4_1","unstructured":"U.S. Food and Drug Administration. Simponi (golimumab) injection for subcutaneous use: US prescribing information. Silver Spring (MD): US Food and Drug Administration; 2011 [cited 2026 Mar 7]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125289s0064lbl.pdf"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-021082"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2016.1221759"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X241295920"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.064808"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-024-00361-3"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02746-5"},{"key":"e_1_3_7_11_1","unstructured":"Food and Drug Administration. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations guidance for industry draft guidance. 2019 [cited 2026 Mar 5]. Available from: https:\/\/www.fda.gov\/media\/125484\/download"},{"key":"e_1_3_7_12_1","unstructured":"European Medicines Agency. Committee for medicinal products for human use (CHMP) guideline on similar biological medicinal products. 2014 [cited 2026 Mar 5]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1851364"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34436"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab630"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204195"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key309"},{"key":"e_1_3_7_19_1","unstructured":"U.S. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. Silver Spring (MD): U.S. Food and Drug Administration; 2015 Apr [cited 2026 Mar 9]. Available from: https:\/\/www.fda.gov\/media\/82647\/download"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2663826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:38:01Z","timestamp":1779950281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2026.2663826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/14712598.2026.2663826"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2026.2663826","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}